According to reports from The Economic Times, brokerages continue to maintain selectively positive outlooks on key large-cap names across pharmaceuticals, automobiles, and healthcare sectors despite near-term headwinds. Analysts are backing companies with strong growth visibility, robust expansion plans, and improving margin profiles. The recommendations come amid challenges linked to pricing pressure, rising costs, and execution delays in these sectors.
As reported by The Economic Times, Elara Securities highlighted the strength of Sun Pharmaceutical Industries' specialty business and the potential for continued growth. The brokerage maintains a positive outlook on the pharmaceutical company, citing the robust performance of its specialty segment as a key driver for future expansion. The recommendation reflects confidence in the company's ability to capitalize on its strong specialty business foundation.
According to The Economic Times, Citi maintains a buy rating on Eicher Motors, while Goldman Sachs retains its buy recommendation on Max Healthcare Institute. These recommendations span across different sectors, demonstrating the selective nature of brokerage coverage. The positive ratings suggest analysts view these companies as well-positioned to navigate current market challenges while maintaining growth trajectories.
Recent brokerage reports show mixed but generally positive sentiment on Eicher Motors following Q4 FY26 results. Nuvama Institutional Equities retained its 'Buy' call with an unchanged target price of ₹8,100, citing strong performance with revenue growing 16% YoY to ₹6,080 crore and EBITDA surging 20% to ₹1,510 crore. Elara Capital also reiterated a 'Buy' rating while trimming its target price to ₹9,001 from ₹9,300, implying a potential upside of around 29% from the assessed price of ₹6,982. However, Motilal Oswal maintained a 'Neutral' rating citing export uncertainty, while JM Financial reiterated its 'Reduce' call despite slightly raising its target price.
As reported by The Economic Times, the brokerage recommendations indicate a cautiously optimistic stance on large-cap stocks despite prevailing market uncertainties. Analysts are focusing on companies with demonstrable growth visibility and margin improvement potential, suggesting that while near-term challenges persist, selective opportunities remain in the pharmaceutical, automobile, and healthcare sectors. Recent developments show sustained demand for premium segments and strong product pipelines supporting long-term growth prospects.
